StockData
Burning Rock Biotech Ltd logo

Burning Rock Biotech Ltd (BNR) stock

BNRNasdaqServices-Medical Laboratories
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$13.07+0.57 (+4.56%)

Close on Nov 18, 2026Market cap $142.28MP/E –Yield –

Earnings

Burning Rock Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
CN¥126.30M
+0.2% on a year earlier
EPS, Q4 FY2025
-0.15 CNY
-0.79 CNY a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Burning Rock Biotech's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 13, 2026after the closeCN¥126.30M+0.2%-0.15 CNYRelease
Q4 FY2024ended Dec 31, 2024Mar 25, 2025before the openCN¥126.00M+4.0%-0.79 CNYRelease
Q4 FY2023ended Dec 31, 2023Mar 28, 2024during market hoursCN¥121.10M–-1.58 CNYRelease
Q4 FY2022ended Dec 31, 2022Mar 28, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Aug 31, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 22, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Burning Rock Biotech has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Burning Rock Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Burning Rock Biotech filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?